Russian Institute will provide Upstream with drug candidates for in vivo testing.
Upstream Biosciences inked an agreement with Lomonosov Moscow State University (MSU) related to tropical parasitic diseases and cancer. The collaborators will work on the chemical synthesis of compounds that Upstream intends to test for efficacy and toxicity.
Under the terms of this one-year renewable agreement, the Combinatorial Chemistry Center of the Chemistry Department at MSU will provide Upstream with drug candidates for in vivo testing against diseases such as malaria, leishmaniasis, and trypanosomiasis. MSU will also incorporate the in vivo test results from Upstream’s ongoing preclinical studies to synthesize additional compounds for the company’s chemical libraries.
Initial in vivo studies of Upstream’s candidates against trypanosomiasis parasites are expected to be completed in early 2008.
